Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
🚨 Attention RMTG Shareholders & Bidders — Urgent Update
If you hold shares or currently have a bid placed on RMTG, I need you to DM me as soon as possible. There’s an important update that affects the direction of the stock and I want to keep this in the hands of investors who actually care about the upside.
Let’s coordinate — the timing couldn’t be more critical.
Agree. With the low float, this could fly.
Exosomes are redefining the way we approach neurodegeneration.
— Global Stem Cells Group (@StemCellGroupUS) July 8, 2025
With their unique ability to cross the blood-brain barrier, exosomes are being studied as carriers of therapeutic molecules for Alzheimer’s, Parkinson’s, and brain injury recovery.#stemcell | $RMTG pic.twitter.com/ntSFJ762wE
I think the interest here will trickle in for a little while, and then one of these days the damn will bust(hopefully). Won’t take much interest to take this back to 35¢
I’ve emailed them a number of times to voice my frustration with the communication…. Took em two years to start getting active on social media.
I think Dave was gun shy over LAHO(don’t blame him).
Technically, it was their current status that delisted them, but at the same time, there were other companies far more delinquent than them, and they were working on getting current. Dave blamed the pumpers, and the price spike for delisting, more than their delinquent filings that were a problem before he became CEO.
I was super speed in being proactive on that buy back, and am friends with an investment banker that helped me out…. When I told him the story he laughed and shook his head, said he gave me a 1% chance I would see any money let alone being made whole…. But about a month later I received a wire. After that, MSSV(now RMTG) was a no brained buy for me with the profits from LAHO
That was the best "busted penny stock" experience I've had. Took about 2 years to receive the money, but I also made out well on that, and because of that I have shares here
Then Dave came up with a stock buyback plan for affected LAHO shareholders….. an 8.2 million dollar program, which I and many others recovered their money.
Your warning of Dave’s history is a hugely positive story from the perspective of OTC traders. It all leads to RMTG
Those facts are fuzzy….. under Dave LAHO went from .0004 to .0048ish(not $3.00 lol), perhaps the $3 was well before Dave?
They were working on completing financials, but that share price uptick put them on SEC radar, and the SEC suspended them, and Dave decided to make LAHO private
Then Dave came up with a stock buyback plan for affected LAHO shareholders….. an 8.2 million dollar program, which I and many others recovered their money.
If nothing else, the LAHO story shows the solid integrity of Dave
David was president of Lans holdings, stock shot up from penny’s to $3+, then halted, open back up sub penny and now it’s gone.
2019: Planned to acquire Global Stem Cells Group, Inc., but the acquisition was later cancelled. The company also faced a temporary trading suspension by the SEC due to a lack of current and accurate information.
Pretty light volume every trading day
Hey Brandy — I totally understand wanting to do your due diligence — leadership matters, especially in this space.
Just for perspective, RMTG’s CEO actually has a solid track record, including successfully taking a prior company public on NASDAQ. He’s been married 33 years, raised five kids, and built a career around helping people through regenerative medicine.
Since taking the reins here, RMTG has reported three straight profitable quarters, expanded to 21 countries, and is gearing up to benefit from new state legislation in Florida — all with just 11.5M shares in the float.
If you’re referring to something specific, I’m open to learning more — but from everything I’ve seen, he’s building something real here.
Thanks again for sharing —
— Andy
Definitely agree. Bid/ask is starting to show signs of strength — nice to see some weight on the bid again and the spread tightening up a bit.
If we can hold that .035 and get some volume flowing, I think .044 gets tested fast. Been quiet, but the chart is primed for a move once momentum picks up. The pieces are falling into place.
Definitely agree. Bid/ask is starting to show signs of strength — nice to see some weight on the bid again and the spread tightening up a bit.
If we can hold that .035 and get some volume flowing, I think .044 gets tested fast. Been quiet, but the chart is primed for a move once momentum picks up. The pieces are falling into place.
Definitely looking healthier with that bid/ask
Looking for volume and price ⬆️. Holding a nice chunk now and would buy more into strength.
Oooohhh, that sounds vague and ominous….
Be careful of this CEO, he has a history.
RMTG Was Up 68% — Light Volume, But the Tape’s Tightening
RMTG hit +68% earlier today on light action — someone took 5K at $0.038, then cleared another 5K at $0.043. Not huge volume, but it moved. Then a single 100-share hit on the $0.035 bid pulled the gain back to +38% — classic OTC percentage shake.
Let’s be honest — the volume’s still light, but this week has shown signs of life:
• 40K traded one day,
• 57K another,
• and now we’re seeing $0.035 x $0.044 with 30K sitting on the bid.
The spread is tightening and the tape is starting to firm up.
What makes this one different? RMTG is fully reporting, has 11.5M float, and has posted three consecutive profitable quarters. That’s rare for a sub-5¢ OTC play.
If you’re in or just watching, hit me up. Always down to bounce ideas.
– Andy
You nailed it — when 95%+ of the shares are locked up with holders waiting for a much higher PPS, we’re obviously not dealing with a normal float. That’s why I’ve been focused on changing what we can control — volume, visibility, and daily outreach.
We’ve got new eyes coming in every day through direct calls, message board traffic, social media, emails and a broader visibility push. It won’t take much with the structure this tight — a few motivated bids and we’re through the .04s fast.
The setup is here. It just needs ignition — and we’re working on exactly that.
Another group I’m talking to have discussed the possibility that it’s a victim of being the beneficiary of 95% of their shares held by very long term, loyal shareholders and it would take quite the price improvement to shake any shares loose, but that has caused quite the liquidity problem.
Totally agree — and honestly, that’s why I stepped in.
This thing’s been flying under the radar with real fundamentals in place. I just sent the NOBO list for enrichment so I can directly contact the core holders — not just to chat, but to organize something coordinated. I want to align a few of the bigger hands behind the scenes before we put real pressure on the tape.
I’m planning a movement — volume, visibility, engagement. But I don’t want it to be random noise. If we time it right and the float stays clean, it could move fast.
Would be good to connect — always better when the right people are on the same page. DM me if you’re down to chat.
Seems like the biggest issue is visibility on all the positive developments for RMTG….. Most companies, it’s like pulling teeth to get updates, RMTG puts updates out there daily….. Need more eyeballs to see them!
RMGT subsidiary is always posting on Facebook as well to update their customers about upcoming events and new products almost daily.
Check out their website, they frequently give updates and PRs there.
They have an absolute ton of updates on their twitter feed…. Their communication on twitter is what otc traders can only dream of with 99.9% of companies.
🏆👍 $RMTG As the market embraces the reality of Stem Cell Therapies and other Regenerative Medical Solutions, know that RMTG/GSCG has the highest quality products available. Do your research! 🔍 https://t.co/4xupvCSO4m
— $RMTG (Formerly MSSV) (@RMTG_RegenMedTG) June 27, 2025
📣 RMTG — .044s Just Got Taken Out on Only 4,500 Volume 🤯
Last trade: .044 | Bid: .035 | Ask: .0486
This thing is paper thin on the ask. Only 4,500 shares were enough to clean out .044 — imagine what happens when real volume shows up. One small slap and it jumps.
But this isn’t just a technical move — the fundamentals are already there:
✅ Positive EBITDA Margin: +12.2%
✅ Operating Profit Last Q: $134K
✅ Receivables Turnover: 155x — cash cycles FAST
✅ Free Cash Flow Per Share: +$0.05
✅ Return on Equity (5Y Avg): +84.7%
📈 Revenue up 67% YoY
🌍 26 Clinics in 21 Countries
📦 New recurring revenue model launched (locked-in supply contracts)
?
This is a classic setup:
⚡ Micro float
⚡ Tight spread
⚡ Undiscovered cash-flow-positive play
⚡ One or two buyers could blow through .05 and beyond
“The chart’s not just ready — the business is finally catching up.”
Anyone Still Watching $RMTG or Am I the Last One Left in the Room?
Just checking in — feels like it’s been crickets on this board lately.
Still holding my position and watching closely.
The chart is tight, the float is low, and they’re still running 26 clinics across 21 countries with profitable quarters behind them.
No fluff. No daily fluff PRs. But also… no hype. Which is why I think this thing’s still massively underpriced.
Curious who else is still here? Let’s get a thread going — thoughts on when visibility starts to pick up?
Anyone thinking about averaging down, holding strong, or just watching from the sidelines?
Let’s breathe some life back in here.
— Andrew
Anyone Still Watching $RMTG or Am I the Last One Left in the Room?
Just checking in — feels like it’s been crickets on this board lately.
Still holding my position and watching closely.
The chart is tight, the float is low, and they’re still running 26 clinics across 21 countries with profitable quarters behind them.
No fluff. No daily fluff PRs. But also… no hype. Which is why I think this thing’s still massively underpriced.
Curious who else is still here? Let’s get a thread going — thoughts on when visibility starts to pick up?
Anyone thinking about averaging down, holding strong, or just watching from the sidelines?
Let’s breathe some life back in here.
— Andrew
Love the energy! 🔥 You nailed it — 3 straight profitable quarters and still flying under most people’s radar.
I’ve recently stepped in to help bring visibility to the $RMTG story. Would be great to connect with other long-term investors who actually see the potential here. Sharing updates, staying informed, and supporting the story together can go a long way.
On days with strong news, even light bid support makes a difference. This thing’s thin — it doesn’t take much for it to start moving with the right interest behind it.
Feel free to reply or message me — always down to talk shop. 💬📈
So exciting 🙌 for me $$$ 3 quarters of back-to-back operational profitability 📈 I've survived all the haters $RMTG 💰 for the win 🏆
RMTG market cap is tiny along with a micro float. Just add news and this can rocket 🚀
https://www.otcmarkets.com/stock/RMTG/security
RMTG $$$
New to the board. Just saying “Hi” to everyone.
So true ! Need to get this story out there
10K looks decent on the revenue side. I haven’t had much time to read in between the lines…. But I will take nearly double the revenue QoQ!!
Thanks for your service. Best of luck to you.
$19 million in promissory notes...
Yes it would be a fun ride. Such a low float and so positives things going on. I’ll hang out and see what happens. I’ve been here over 5 years, what’s another 5. Best of luck to you.
It’s really hard to say, like you said, it will take eyeballs…. I know when the buyback started it went from .05 to .35 with just a little volume…. Sat there for a while, then a very low volume slow bleed to below a penny. If it catches enough eyes, it’s just a simple supply and demand issue, with too many people chasing too few shares….. that’d be a fun ride, haha
That’s where I’m at. I have some shares and would love to buy more, but I’d feel more comfortable buying with volume.
Any thoughts on where this goes? Think it will eventually get some attention on social media platforms? Seems like nobody really knows about RMTG. Investing/trading community seems to have no idea this exists.
Catch 22 with these types of stocks. Low or no volume. Volume comes from folks buying the stock, but people don’t feel comfortable buying a stock that doesn’t have volume.
Also, there are 12.5 million shares available for trade and probably close to 10 million shares owned by people who have owned them for 4 years or more.
New Dubai Clinic
📈 Welcome to our newest clinic in Dubai, UAE 🔥$RMTG
— $RMTG (Formerly MSSV) (@RMTG_RegenMedTG) November 30, 2024
Regenerative Medical Technology Group https://t.co/kfFgEuG03G
But I agree, I am surprised they have kept this a secret like they have. I’d imagine they just don’t want to draw attention or have PPS movement at this time. Nobody talking about it on any platform.
Shhhh 🤫. It’s a secret ticker flying under the radar right now. I’m waiting for volume and when it’s no longer secret. Holding a few shares and will load the rest when the time seems right.
WTF good financial news and the stock turns to S--t what's going on ?
Bought a starter and will add when volume picks up.
Followers
|
342
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
50950
|
Created
|
01/07/08
|
Type
|
Free
|
Moderators |
LAS VEGAS, NV, Feb. 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a regenerative medicine company is pleased to announce that it will be undergoing a name change from Meso Numismatics Inc. to Regenerative Medical Technology Group Inc. to better reflect the company’s business. The Company will also change its authorized shares outstanding from the current 6.5 billion to 100 million shares. Please see the Information Statement on Schedule 14C filed by the Company on February 2, 2024, and other Company filings at www.sec.gov.
About Meso Numismatics: Meso Numismatics Corp is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group. The Company currently has a network of 26 clinics in 21 countries that carry its banner and has its own clinic in Cancun and is currently building another one in Dubai. The Company distributes stem cells and other regenerative based cell lines, and equipment internationally and also specializes in education and training physicians in the area of regenerative medicine.
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
Forward-Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words “plan”, "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Lans Holdings Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
Investor.relations@mssvinc.com
Telephone: (800) 956-3935
The Cancun clinic is currently active and is finalizing its full build out, which will double its footprint by the end of February. The clinic is also comprised of a lab where stem cell cultures can be produced. The Cancun clinic currently offers numerous procedures for multiple indications including: hormone replacement, autoimmune, neurodegenerative, osteoarthritis, cardiovascular, aesthetic/anti-aging, hair transplant, sports medicine, spinal cord injury, MS, and autism. The Company is in the process of building out a clinic in Dubai that will offer similar procedures to those in the Cancun location. The Dubai clinic is expected to be fully operational by the end of the second quarter of this year.
The Company plans to close on two additional locations for new clinics, one by the end of the third quarter and one by the end of the fourth quarter of this year. Both of these clinics are expected to be operational by the end of the second quarter of 2025.
The Company also has a collaboration with an Istanbul based clinic where the Company refers patients and receives patient referrals on various patient procedures.
The Company operates in the stem cell therapy market, which is expected to grow from $11.2 billion in 2022 to $31.4 billion by 2030 according to Precedence Research. The Company has also entered the exosome market, which is expected to grow from $250 million in 2022 to $3.2 billion by 2032 according to Global Market Insights.
The Company is actively collaborating with leading research institutions, universities, and industry experts to accelerate the development and commercialization of regenerative medical solutions. These partnerships create a collaborative ecosystem that fosters scientific excellence and ensures that the Company remains at the forefront of innovation, contributing to medical advancements and expanding its range of products. With a global vision, the Company is dedicated to making a positive impact on healthcare worldwide. The company is exploring opportunities to expand its reach and make its cutting-edge medical procedures accessible to patients across borders.
"We are thrilled to be at the forefront of regenerative medicine, bringing hope to patients and pushing the boundaries of what is possible in biotechnology. Our commitment to innovation and collaboration underscores our mission to make a lasting impact on the lives of individuals facing challenging medical conditions," said David Christensen, CEO and President of the Company.
The driving forces behind Global Stem Cells Group's strategy to increase revenue in 2024 involve a multifaceted approach within the rapidly expanding stem cell therapy market. As the wholly-owned subsidiary of the Company, Global Stem Cells Group specializes in cutting-edge stem cell research collaborations and physician training. The key components contributing to revenue growth include:
Certified Training Courses for Physicians - Offering specialized and certified training courses to physicians, ensuring they are equipped with the latest knowledge and skills in stem cell therapies. The Company is internationally recognized as an expert in the field of stem cells and regenerative medicine.
Manufacturing and Sales of the Latest Technology, Supplies, and Equipment - Engaging in the production and sale of state-of-the-art technology, supplies, and equipment related to stem cell applications, catering to the needs of medical professionals in the field.
Research and Development of Clinical Protocols - Investing in research and development collaborations to create advanced clinical protocols for stem cell applications, enhancing the efficacy and safety of treatments.
Regenerative Medical Clinics - Cancun, Dubai, and Istanbul, Provide standardized regenerative medical treatments. These treatments cover a spectrum of health issues, including musculoskeletal disorders, autoimmune diseases, aesthetics, and anti-aging.
Franchising Network of Regenerative Medical Practitioners - Establishing a network of franchised regenerative medical practitioners, potentially increasing the geographical reach and accessibility of stem cell treatments. Currently 26 clinics in 21 countries carry the Company's banner. This allows the Company to raise its global profile and branding and assist the company in bringing patients to its own clinics.
Turnkey Solutions for Stem Cell Processing Center Installation & Management - Offering comprehensive complete solutions for the installation and management of stem cell processing centers, providing a one-stop solution for practitioners entering the field.
By diversifying into these key areas Global Stem Cells Group aims to tap into various aspects of regenerative medicine, creating revenue streams through education, product sales, research, patient services, and strategic partnerships within the stem cell therapy market.
"We are excited to announce our significant growth across multiple channels, showcasing the strength and diversity of our business. The success in training, product sales, equipment sales, and patient procedures reflects our commitment to excellence in every facet of regenerative medicine," said Benito Novas, CEO and Founder of Global Stem Cells Group.
This press release should be read in conjunction with all of the Company's filings on www.sec.gov
About Meso Numismatics: Meso Numismatics, Inc. is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group. The Company currently has a network of 26 clinics in 21 countries that carry its banner and has its own clinic in Cancun and is currently building another one in Dubai. The Company distributes stem cells and other regenerative based cell lines and equipment internationally and also specializes in educating and training physicians in the area of regenerative medicine.
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
Forward Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Lans Holdings Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
Investor.relations@mssvinc.com
Telephone: (800) 956-3935
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |